Novel direct curve comparison metrics for bioequivalence

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Pharmaceutical Sciences
• Biostatistics

Background:

• Bioequivalence studies are crucial for generic drug approval.
• Traditional metrics like Cmax and AUCi have limitations in assessing drug product performance.
• Direct Curve Comparison (DCC) offers an alternative approach to profile analysis.

Purpose of the Study:

• To develop and evaluate four novel Direct Curve Comparison (DCC) metrics.
• To assess the distribution properties and performance characteristics of these new DCC metrics.
• To compare the utility of DCC metrics against traditional bioequivalence measures (Cmax and AUCi).

Main Methods:

• Calculated DCC metrics (rho, rhom, deltaa, deltas), Cmax, and AUCi from two bioequivalence studies.
• Utilized data from sustained-release carbamazepine formulations with varying profile similarities.
• Compared DCC metric values and confidence intervals with Cmax and AUCi.

Main Results:

• The novel DCC metrics demonstrated more favorable, less skewed distributions compared to Cmax and AUCi ratios.
• DCC metrics provide a comprehensive profile comparison by utilizing all data points, unlike Cmax and AUCi.
• Proposed bioequivalence acceptance criteria for the new DCC metrics: p ≤ 1.40, rhom ≤ 0.35, deltaa ≤ 0.27, and deltas ≤ 0.102.

Conclusions:

• The developed DCC metrics, especially rhom, show significant promise as effective measures for assessing drug exposure in bioequivalence studies.
• These metrics offer a more robust and sensitive evaluation of drug product performance.
• DCC metrics represent a potential advancement in bioequivalence assessment methodologies.